On April 23, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved loncastuximab tesirine-lpyl (ZYNLONTA, ADC Therapeutics), a CD-19-directed antibody and alkylation agent conjugate, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma. This is the first and only CD-19-targeted antibody drug conjugate as a single agent for relapsed/refractory DLBCL.
“Diffuse large B-cell lymphoma is the most common type of lymphoma, however, relapsed or refractory disease remains a significant area of unmet need,” said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation. “The approval of loncastuximab tesrine-lpyl offers patients a new treatment option and new hope for improving outcomes.”
For more information on the FDA approval of loncastuximab tesirine-lpyl (ZYNLONTA), visit the FDA’s website FDA’s website. To learn more about treatment options for DLBCL, visit the DLBCL Learning Center.